195 related articles for article (PubMed ID: 25918294)
1. Biliary tract cancers: understudied and poorly understood.
Chan E; Berlin J
J Clin Oncol; 2015 Jun; 33(16):1845-8. PubMed ID: 25918294
[TBL] [Abstract][Full Text] [Related]
2. New developments in systemic therapy for advanced biliary tract cancer.
Morizane C; Ueno M; Ikeda M; Okusaka T; Ishii H; Furuse J
Jpn J Clin Oncol; 2018 Aug; 48(8):703-711. PubMed ID: 29893894
[TBL] [Abstract][Full Text] [Related]
3. Biliary tract carcinomas: from chemotherapy to targeted therapy.
Marino D; Leone F; Cavalloni G; Cagnazzo C; Aglietta M
Crit Rev Oncol Hematol; 2013 Feb; 85(2):136-48. PubMed ID: 22809696
[TBL] [Abstract][Full Text] [Related]
4. Toward personalized treatment of advanced biliary tract cancers.
Geynisman DM; Catenacci DV
Discov Med; 2012 Jul; 14(74):41-57. PubMed ID: 22846202
[TBL] [Abstract][Full Text] [Related]
5. The choice for the optimal therapy in advanced biliary tract cancers: Chemotherapy, targeted therapies or immunotherapy.
Palmieri LJ; Lavolé J; Dermine S; Brezault C; Dhooge M; Barré A; Chaussade S; Coriat R
Pharmacol Ther; 2020 Jun; 210():107517. PubMed ID: 32109491
[TBL] [Abstract][Full Text] [Related]
6. Cancers of the biliary system.
Malka D; Dromain C; Landi B; Prat F; De Baere T; Delpero JR; Chiche L
Gastroenterol Clin Biol; 2006 Sep; 30 Spec No 2():2S62-2S74. PubMed ID: 17151565
[No Abstract] [Full Text] [Related]
7. Carcinoid and neuroendocrine tumors: building on success.
Kunz PL
J Clin Oncol; 2015 Jun; 33(16):1855-63. PubMed ID: 25918282
[TBL] [Abstract][Full Text] [Related]
8. Biliary tract cancers: SEOM clinical guidelines.
Benavides M; Antón A; Gallego J; Gómez MA; Jiménez-Gordo A; La Casta A; Laquente B; Macarulla T; Rodríguez-Mowbray JR; Maurel J
Clin Transl Oncol; 2015 Dec; 17(12):982-7. PubMed ID: 26607930
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant therapy for resected extrahepatic cholangiocarcinoma: a review of the literature and future directions.
Anderson C; Kim R
Cancer Treat Rev; 2009 Jun; 35(4):322-7. PubMed ID: 19147294
[TBL] [Abstract][Full Text] [Related]
10. Treatment of patients with unresectable advanced carcinoma of biliary tract - chemotherapy and surgical resection.
Morise Z; Sugioka A; Tanahashi Y; Okabe Y; Ikeda M; Kagawa T; Takeura C
Anticancer Res; 2009 May; 29(5):1783-6. PubMed ID: 19443404
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer.
Furuse J; Okusaka T; Ohkawa S; Nagase M; Funakoshi A; Boku N; Yamao K; Yamaguchi T; Sato T
Cancer Chemother Pharmacol; 2009 Dec; 65(1):113-20. PubMed ID: 19404641
[TBL] [Abstract][Full Text] [Related]
12. Regional chemotherapy in biliary tract cancers--a single institution experience.
Melichar B; Cerman J; Dvorák J; Jandík P; Mergancová J; Melicharová K; Tousková M; Krajina A; Voboril Z
Hepatogastroenterology; 2002; 49(46):900-6. PubMed ID: 12143237
[TBL] [Abstract][Full Text] [Related]
13. Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice.
Jain A; Kwong LN; Javle M
Curr Treat Options Oncol; 2016 Nov; 17(11):58. PubMed ID: 27658789
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive review of the diagnosis and treatment of biliary tract cancer 2012. Part I: diagnosis-clinical staging and pathology.
Marsh Rde W; Alonzo M; Bajaj S; Baker M; Elton E; Farrell TA; Gore RM; Hall C; Nowak J; Roy H; Shaikh A; Talamonti MS
J Surg Oncol; 2012 Sep; 106(3):332-8. PubMed ID: 22488652
[TBL] [Abstract][Full Text] [Related]
15. Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design.
Sicklick JK; Fanta PT; Shimabukuro K; Kurzrock R
Cancer Metastasis Rev; 2016 Jun; 35(2):263-75. PubMed ID: 26857926
[TBL] [Abstract][Full Text] [Related]
16. Second-line therapy in advanced biliary tract cancer: what should be the standard?
Cereda S; Belli C; Rognone A; Mazza E; Reni M
Crit Rev Oncol Hematol; 2013 Nov; 88(2):368-74. PubMed ID: 23786845
[TBL] [Abstract][Full Text] [Related]
17. Molecular Targets in Biliary Carcinogenesis and Implications for Therapy.
Oyasiji T; Zhang J; Kuvshinoff B; Iyer R; Hochwald SN
Oncologist; 2015 Jul; 20(7):742-51. PubMed ID: 26025932
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapeutic Approaches to Biliary Cancer.
Shah UA; Nandikolla AG; Rajdev L
Curr Treat Options Oncol; 2017 Jul; 18(7):44. PubMed ID: 28660602
[TBL] [Abstract][Full Text] [Related]
19. [Prospective randomized trial comparing 1/2 FAM (5-fluorouracil (5-FU) + adriamycin + mitomycin C) versus palliative therapy for the treatment of unresectable pancreatic and biliary tract carcinomas (the 2nd trial in non-resectable patients). Japanese Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract].
Takada T; Kato H; Matsushiro T; Nimura Y; Nagakawa T; Nakayama T; Yamauchi H; Ogata Y; Shimada H; Miyakawa S; Yamaguchi A; Sakoda K; Yasuda H; Tsukada K; Yoshida K; Ashida H; Ishikawa Y; Kotoura Y; Kinoshita H; Kajiwara T; Watanabe G; Uchimura M; Funabiki T; Ikeda S; Okada S
Gan To Kagaku Ryoho; 1996 May; 23(6):707-14. PubMed ID: 8645022
[TBL] [Abstract][Full Text] [Related]
20. Movement of a novel serum tumour marker, RCAS1, in patients with biliary diseases.
Enjoji M; Yamaguchi K; Nakamuta M; Nakashima M; Kotoh K; Tanaka M; Nawata H; Watanabe T
Dig Liver Dis; 2004 Sep; 36(9):622-7. PubMed ID: 15460847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
